Bioera Valuation

Is BIEM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIEM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BIEM (€0.04) is trading below our estimate of fair value (€0.36)

Significantly Below Fair Value: BIEM is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIEM?

Key metric: As BIEM is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BIEM. This is calculated by dividing BIEM's market cap by their current revenue.
What is BIEM's PS Ratio?
PS Ratio	1.5x
Sales	€606.00k
Market Cap	€932.60k

BIEM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.6x
Enterprise Value/EBITDA	-1.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does BIEM's PS Ratio compare to its peers?

The above table shows the PS ratio for BIEM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	6.3x
VOY Mendell Helium	4.3x	n/a	UK£1.3m
BAR Brand Architekts Group	0.5x	n/a	UK£7.8m
CLAI Cel AI	5.8x	n/a	UK£316.2k
PXS Provexis	14.8x	n/a	UK£11.8m
BIEM Bioera	1.5x	n/a	€932.6k

Price-To-Sales vs Peers: BIEM is good value based on its Price-To-Sales Ratio (1.5x) compared to the peer average (10.3x).

Price to Sales Ratio vs Industry

How does BIEM's PS Ratio compare vs other companies in the European Personal Products Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap

7 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: BIEM is expensive based on its Price-To-Sales Ratio (1.5x) compared to the European Personal Products industry average (1.3x).

Price to Sales Ratio vs Fair Ratio

What is BIEM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIEM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BIEM's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Ontex Group

€620.0m

Develops, produces, and supplies personal hygiene products and solutions for baby, feminine, and adult care in Belgium, the United Kingdom, the United States, Italy, France, and internationally.

0QVQ

€7.59

2.0%

6.6%

McBride

UK£182.8m

Manufactures and sells private label household and personal care products to retailers and brand owners in the United Kingdom, Germany, France, Italy, Spain, rest of Europe, Asia-Pacific, and internationally.It operates through five segments: Liquids, Powders, Unit dosing, Aerosols, and Asia Pacific.

MCBL

UK£1.05

0.5%

71.3%

Accrol Group Holdings

UK£123.7m

Engages in the soft tissue paper converting business in the United Kingdom and Europe.

ACRL

UK£0.39

9.6%